Heron Therapeutics’ High-Wire Act: Can a Fast-Growing Acute Care Franchise Outrun Its Balance Sheet Risk?

On a March morning in 2026, the whiteboards in Heron Therapeutics’ San Diego commercial “war room” tell a story in three colors. One panel tracks weekly vials of ZYNRELEF, the company’s long-acting, non-opioid pain drug used in operating rooms. Another shows APONVIE, an intravenous anti-nausea therapy used after surgery, with unit trends bending sharply upward since a dedicated sales team hit the field the previous summer. On the far wall, a chart of first-quarter net sales arcs out of a deep January trough: after the worst month the company has seen in years, March revenue pushes past $15 million.

Chief executive Craig Collard narrates the quarter on the Q1 2026 earnings call: total net sales of $34.7 million, down from $40.6 million in Q4 as seasonal deductibles reset and two weeks of severe winter weather delayed elective surgeries across the United States. Yet within that disruption, the core bet holds. Heron’s Acute Care portfolio still grew 32 percent year over year, with ZYNRELEF up 27 percent and APONVIE more than 50 percent versus the prior-year quarter.

Behind those swings in monthly revenue lies a company that has spent four decades reinventing itself. Heron began life in the early 1980s as A.P. Pharma, a drug-delivery specialist whose value proposition was technological. Today it lives or dies on the ability of a relatively small field force, distributor incentive programs and reimbursement wins to push a handful of hospital products into daily use. The question for investors is no longer whether the Biochronomer delivery platform works, but whether Heron can convert its maturing oncology base and fast-growing Acute Care franchise into sustained, profitable growth before its leveraged balance sheet and product concentration risks catch up.

Heron’s story starts long before ZYNRELEF vials and APONVIE infusion bags. Founded in 1983 as A.P. Pharma, Inc., the company went public in 1987 during an early wave of biotech enthusiasm. Its core pitch was the same one it still makes today: that better drug delivery can turn existing molecules into more useful medicines.

Biochronomer, the polymer-based platform that underpins Heron’s products, is essentially a controlled-release system. Instead of patients taking multiple doses of a short-acting drug, Biochronomer formulations are designed so that one injection slowly releases medication over days or even weeks. In supportive care settings like chemotherapy-induced nausea and postoperative pain, that can mean fewer injections, more predictable symptom control and potentially fewer hospital resources spent on rescue treatments.

For years as A.P. Pharma, the company largely licensed and partnered its technology rather than building its own commercial infrastructure. That approach kept costs relatively low but also limited upside. A key turning point came in January 2014, when A.P. Pharma rebranded as Heron Therapeutics, Inc. The new name signaled a strategic reset: instead of a platform-for-hire, Heron aimed to become a fully integrated biotech with its own marketed products.

The first proof points came in oncology supportive care. Heron developed SUSTOL, an extended-release formulation of granisetron, for chemotherapy-induced nausea and vomiting (CINV). By stretching the activity of a familiar anti-nausea drug across several days, SUSTOL illustrated how Biochronomer could convert a generic ingredient into a potentially differentiated product in a highly symptomatic setting.

Next came CINVANTI, an intravenous formulation of aprepitant used to prevent both acute and delayed CINV. This product was not itself a Biochronomer formulation, but it fit Heron’s emerging thesis: focus on supportive care niches where workflow, dosing convenience and predictable symptom control matter as much as headline efficacy. Oncology infusion clinics and hospital outpatient departments became Heron’s proving ground for commercial execution.

That mission statement is broad, but it provides a through-line from the 1980s to today. Whether delivering chemotherapy anti-nausea drugs over several days or numbing a joint replacement incision for the first two or three days after surgery, Heron’s products are designed to smooth out the rough edges of existing care. As the company shifted from research platform to commercial operator, the focus tightened from technology to specific niches inside hospitals and oncology practices where those incremental improvements could support premium pricing.

Heron’s oncology supportive care franchise is not glamorous, but it is foundational. SUSTOL and CINVANTI gave the company its first consistent revenue stream and relationships across oncology practices, community cancer centers and hospital outpatient departments. Those relationships now underpin the Acute Care push.

Chemotherapy-induced nausea and vomiting is one of the more debilitating side effects of cancer treatment. Patients often receive combinations of drugs before chemotherapy to prevent symptoms that can last several days. SUSTOL, by extending the action of granisetron through the Biochronomer platform, aimed to reduce breakthrough nausea without daily dosing. CINVANTI, as an intravenous formulation of aprepitant, slotted into existing antiemetic regimens but with the convenience and familiarity of a branded IV product supported by Heron’s commercial team.

Financially, oncology supportive care has become Heron’s cash-flow anchor. In 2025, the franchise generated just over $105 million in net revenue. That was a 7.8 percent decline compared with 2024, but management is explicit that the drop is primarily due to the planned wind down of SUSTOL, which the company intends to discontinue through 2026, rather than competitive erosion in CINVANTI.

Within that shrinking franchise, CINVANTI is the workhorse. In Q1 2026, Heron reported that CINVANTI maintained an exit market share of 25 percent in the NK1 class of antiemetics. That quarter, oncology products delivered $21.1 million in revenue, with CINVANTI contributing $20.5 million and SUSTOL $0.6 million as the wind down continued.

For investors, this presents a clear tension. Oncology supportive care is relatively predictable and high margin, but it is not growing. As SUSTOL disappears and CINVANTI holds roughly flat to modestly down under competitive and pricing pressure, the oncology line is more a bond than a stock: a gradually declining cash stream that can fund a finite period of investment elsewhere.

Management’s strategy is to use that oncology “bond” to fuel growth in Acute Care and the broader pipeline. In 2025, Heron generated approximately $155 million in total net revenues, of which just over $105 million came from oncology. Acute Care products made up the balance, but their growth rate far outstripped the oncology franchise. The stability of oncology revenue has so far underwritten bets in operating rooms, where the company is more exposed to procedure volumes, weather and hospital budget cycles.

The risk is that the oncology base erodes faster than expected or faces a sharp competitive dislocation, leaving less cash to fund the commercial build-out that is supposed to replace it. With product concentration already high and a leveraged balance sheet in the background, that supportive care beachhead will need to hold steady for the Acute Care push to fully play out.

If oncology supportive care is Heron’s ballast, Acute Care is its sail. The franchise consists of ZYNRELEF, a long-acting local anesthetic for postoperative pain, and APONVIE, an intravenous formulation of aprepitant for postoperative nausea and vomiting. Both are used around the surgical experience, mostly in hospital operating rooms and ambulatory surgery centers, and both depend heavily on hospital protocols, reimbursement and surgeon or anesthesiologist preference.

ZYNRELEF, built on the Biochronomer technology, is designed to release pain relief over the crucial first 72 hours after surgery, a period when opioid use is often highest. By delivering a non-opioid analgesic directly into the surgical site, it aims to reduce the need for systemic opioids and their side effects. APONVIE targets the nausea that often follows anesthesia and opioid use. It is an IV formulation of aprepitant given before surgery to prevent postoperative nausea and vomiting and, like CINVANTI, it leverages the NK1 receptor mechanism in a different setting.

The economic story of these products is striking. In Q4 2025, Acute Care net sales reached $16.3 million, up about 33 percent from $12.3 million in Q3. ZYNRELEF net sales jumped to $12.5 million from $9.3 million, while APONVIE increased to $3.8 million from $3.0 million. Compared with Q4 2024, ZYNRELEF revenue grew 48 percent, APONVIE grew 97 percent and the overall Acute Care franchise increased more than 57 percent year over year.

The start of 2026 showed that this momentum is not immune to macro factors but appears intact on an annual basis. In Q1 2026, Heron’s Acute Care portfolio generated $13.6 million in revenue, with ZYNRELEF contributing $10.2 million and APONVIE $3.4 million. That figure represented 32 percent year-over-year growth despite the seasonally weak first quarter and the weather-related impact on elective surgeries.

These growth rates are the crux of the Heron thesis. The company is trying to transform from a single-franchise oncology player into a two-engine business where Acute Care eventually overtakes oncology as the primary source of revenue and margin. Achieving that will require not just clinical differentiation but deep integration into hospital workflows and reimbursement systems.

Management has been explicit that it will not pursue volume at any price. On the Q1 2026 earnings call, chief operating officer Mark Hensley summarized the company’s stance in front of an internal slide tracking realized prices by product.

That discipline matters because both ZYNRELEF and APONVIE are being rolled out with the support of reimbursement milestones. APONVIE’s permanent J-code (J8502) was announced in Q4 2025. In the United States, a product-specific J-code gives hospitals a clearer path for reimbursement in the buy-and-bill system, reducing uncertainty that can slow adoption.

Clinical guidelines have played a similar role for APONVIE. In Q4 2025, the drug was included in the Fifth Consensus Guidelines for the management of postoperative nausea and vomiting. These consensus documents, produced by expert panels, shape hospital protocols and order sets. Inclusion does not guarantee adoption, but it signals legitimacy and can ease formulary reviews.

Looking ahead, Heron is also trying to make ZYNRELEF easier to use. In Q4 2025, the company placed registration batches of a prefilled syringe presentation on stability testing. It will need 12 months of data before filing for approval, and Collard has guided to a potential approval window in mid to late 2027, assuming a standard 4 to 6 month regulatory review.

The prefilled syringe is a medium-term catalyst rather than an immediate growth driver, but it speaks to a broader theme. In acute surgical settings, even a few extra preparation steps can be a barrier. Heron has already implemented a vial access needle system to simplify ZYNRELEF preparation. A ready-to-use syringe could further lower friction, especially in high-throughput ambulatory surgery centers.

Heron’s public filings devote plenty of space to science and clinical data, but its current strategy is grounded in commercial mechanics. Programs like IGNITE, distributor incentives and targeted sales force expansion are the levers through which the company is trying to translate product attributes into sustained revenue.

IGNITE 1.0, launched in July 2025 with orthopedic distribution partners, is the flagship example. The program provides incentives to distributors to prioritize ZYNRELEF in their existing hospital accounts. Rather than adding more Heron-employed representatives everywhere at once, the company is trying to harness the reach of established orthopedic distributors who are already in the operating rooms and surgeon offices where ZYNRELEF would be used.

By Q4 2025, IGNITE 1.0 covered 2,261 accounts. Within these targeted institutions, ZYNRELEF unit volume more than doubled in just two quarters, rising from roughly 9,000 units in the last pre-IGNITE quarter to more than 19,000 units by the end of 2025. That is 111 percent growth in a subset of accounts that Heron believes represent some of the highest-value surgical volume.

For 2026, IGNITE 2.0 expands that footprint by 38 percent, to 3,109 accounts, adding 848 more institutions to the program. Collard is clear that IGNITE is not a one-off experiment but a structural element of Heron’s growth plan.

Guideline and reimbursement wins sit alongside IGNITE in this commercial engine. APONVIE’s inclusion in the Fifth Consensus postoperative nausea and vomiting guidelines and its product-specific J-code (J8502) lower the institutional barriers to adoption. On the pain side, any incremental reimbursement support for non-opioid options plays a similar role for ZYNRELEF. These milestones do not guarantee success, but they are prerequisites for scaling usage in hospital systems where protocols, formulary tiers and billing rules shape physician behavior as much as individual preferences.

The human element of this engine is notable for a company that once centered its identity on polymer chemistry. Collard, who took over as chief executive with a mandate to sharpen Heron’s commercial focus, is the primary narrator of strategy and capital allocation. Chief operating officer Mark Hensley details the day-to-day metrics of net sales and pricing. Executive vice president and chief development officer Bill Forbes leads the technical evolution of products like ZYNRELEF prefilled syringes and device changes such as the vial access needle. Senior vice president Kevin Warner oversees medical affairs and engagement with guideline authors and key opinion leaders, while legal chief Melissa Jarel keeps public communications within regulatory guardrails.

Heron is also preparing to lean further into its own sales infrastructure. On the Q1 2026 call, Collard confirmed that implementation of a sales force expansion is on track for the third quarter of 2026, with recruitment already underway. The expansion is expected to deepen coverage in high-potential Acute Care geographies and accounts, particularly for APONVIE, where a dedicated sales team launched on July 1, 2025 has already begun to drive higher growth.

For a company with roughly $155 million in annual revenue, these moves represent a meaningful increase in fixed cost. The bet is that targeted expansion, combined with distributor programs and reimbursement clarity, will support enough incremental ZYNRELEF and APONVIE volume to more than cover the added expense. The risk is that hospital budgets, competing products or macro shocks like the Q1 2026 weather events blunt the return on that investment.

Beneath the operational narrative, Heron’s financial statements show a company walking a narrow path between growth and solvency. By several metrics, 2025 was a breakthrough year. The company generated approximately $155 million in total net revenues, delivered adjusted EBITDA of $14.7 million and achieved a gross margin of about 73 percent, exceeding its own EBITDA guidance of $9 million to $13 million.

Strong Q4 2025 performance was a big part of that. That quarter, Heron reported total revenue of $40.588 million and essentially breakeven operating income of $0.038 million, with a net loss of $2.954 million. Acute Care revenues accelerated, and oncology supportive care remained stable enough to support a profitable product mix on an adjusted basis.

The first quarter of 2026, however, highlighted how volatile that progress can be. Total revenue declined to $34.711 million, down about 14.5 percent sequentially, as seasonal patterns and weather disruptions weighed on surgical volumes. Gross profit fell to $24.073 million from $32.939 million, operating income swung to a loss of $4.765 million and net loss widened to $8.111 million. The Q1 2026 gross margin of 69.4 percent was lower than the 2025 average of about 73 percent, reflecting both mix and higher per-unit costs across a smaller revenue base.

Cash flow has been similarly uneven. Operating cash flow was positive $1.331 million in Q3 2025 but negative $10.868 million in Q2 2025, negative $9.184 million in Q4 2025 and negative $1.54 million in Q1 2026. Free cash flow followed the same pattern, swinging from -$11.076 million in Q2 to +$1.331 million in Q3, then back to -$9.184 million in Q4 and -$1.931 million in Q1 2026. These swings reflect the timing of working capital movements, commercial investments and one-time items, but they underscore that Heron is still hovering around breakeven rather than generating consistent cash.

The balance sheet, while improved, remains a central source of risk. At Q2 2025, Heron’s current ratio was just 0.82, with current liabilities exceeding current assets and total stockholders’ equity negative $27.258 million. By Q3 2025, after a key financing and operational improvements, cash and short-term investments had risen to $55.487 million, the current ratio had improved to 2.56 and equity had turned positive at $14.885 million. Those improvements largely held through Q4 2025 and Q1 2026, with equity at $14.333 million and $9.137 million respectively and the current ratio remaining above 2.47.

The financing completed in Q4 2025 was central to that shift. Collard was explicit that the transaction removed a long-standing overhang on the company and reduced capital structure risk by addressing near-term pressures.

Yet the financing did not eliminate leverage. Across mid-2025 through Q1 2026, Heron carried roughly $140 million to $177 million of total debt against a cash and short-term investment balance that ranged from $40.633 million to $55.487 million. At Q1 2026, the company reported $44.784 million in cash and short-term investments, $141.634 million in total debt and $9.137 million in total stockholders’ equity.

Return on equity figures over this period swing widely, from a positive 8.7 percent at Q2 2025 to -117.5 percent at Q3 2025, -20.6 percent at Q4 2025 and -88.8 percent at Q1 2026. These percentages are mechanically extreme because they are calculated on a very small equity base; a few million dollars of net loss or profit can drive triple-digit ROE swings when equity is under $20 million. The more fundamental point is that Heron remains loss-making on a GAAP net income basis, with a Q1 2026 net margin of -23.4 percent despite meaningful top-line growth.

From an investor’s perspective, the key question is whether the company can keep adjusted EBITDA positive, or at least near breakeven, while stepping up commercial spending on IGNITE, sales force expansion and new product presentations. Management has signaled a willingness to allow EBITDA margins to compress in the near term to support longer-term revenue growth. With more than $140 million in debt and only mid-$40 million of cash, however, the margin for error is thin if any of the commercial pillars wobble.

Heron’s improved liquidity and current ratio above roughly 2.5 provide some breathing room across the next few quarters, and the Q4 2025 financing appears to have addressed the most acute balance sheet risks. But the combination of product concentration, uneven cash flow and leverage keeps financial risk central to the narrative. Unlike a larger diversified pharmaceutical company, Heron does not have other divisions to offset a misstep in Acute Care or a faster-than-expected decline in oncology.

Heron’s evolution from A.P. Pharma to a commercial-stage biotech focused on operating rooms and infusion centers has reached a critical juncture. The oncology supportive care franchise is mature and gradually shrinking, while Acute Care is growing rapidly but from a smaller base and with more sensitivity to external shocks. Overlay a still-leveraged balance sheet and volatile cash flows, and the next two years look decisive.

These watchpoints tie back to the central tension in Heron’s story. The company has built a credible commercial engine in two adjacent hospital niches and delivered a year of solid adjusted profitability with high gross margins. Yet it remains a small, leveraged enterprise whose fortunes are tied to the continued growth of a limited set of products and the execution of a relatively lean field force and distributor network.

For investors, the appeal lies in the clarity of the thesis. If Heron can maintain oncology cash flows long enough for ZYNRELEF and APONVIE to scale, keep pricing discipline while benefiting from reimbursement and guideline tailwinds, and navigate its debt profile without material balance sheet strain, today’s volatile earnings could give way to a more durable, less leveraged growth profile. If any of those pieces falter, the same leverage that amplifies upside could magnify downside risk.

In that March 2026 war room, the whiteboards capture only recent months of sales curves and unit trajectories. The longer arc runs from a 1980s drug-delivery start-up to a 2020s hospital specialist trying to prove that it can own a profitable slice of the perioperative and oncology supportive care markets. Over the next two years, the outcome of that experiment will hinge less on polymers and more on the everyday work of selling into hospitals, managing cash and servicing debt.